Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups

Size: px
Start display at page:

Download "Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups"

Transcription

1 Open Dr. Daniel Forler External Innovation Therapeutics Global Drug Discovery, Bayer HealthCare ASTP-Proton Conference Page 1 Bayer Invests Heavily in R&D and is committed to innovation Sustained Innovation Output from all Subgroups Input Output* HealthCare 2.0 billion R&D staff: ~7,500 CropScience 0.8 billion R&D staff: ~4,400 MaterialScience 0.2 billion R&D staff: ~900 26% R&D budget 2012: 3.0 billion 8% 65% Around 40 projects in clinical development or approval procedure, including five products with peak sales potential of 5 billion in total Our integrated product pipeline in crop protection and seed technology contains over 30 projects with estimated launch dates , plus numerous seed varieties Other 27 million R&D staff: ~100 1% New products and applications across all business units; leading-edge process technology for world-scale plants. * As of February 2013 Page 2 1

2 Bayer HealthCare Pharmaceuticals Excellent progress with pipeline Xarelto TM Reduces thrombosis risk Cardiology Oncology Adempas TM Stivarga TM Xofigo TM Reduces pressure in lung arteria Inhibits multiple enzymes that cause tumor growth Acts specifically against bone metastases Innovative products: cardiovascular, cancer & eye diseases Ophthalmology EYLEA TM Inhibits formation of new blood vessels at the back of the eye Page 3 Increasing challenges in the Healthcare Market Aging Population Patients / Consumers gain more Influence Highly efficient healthcare industry Rising costs and pressure on healthcare industry manufacturers Increasing Value Requirements Find options to de-risk research and increase flexibility Understand needs and specifics of diseases prevalent in emerging markets Need to come up with breakthrough innovation From Emerging Markets to Growth Markets Improve molecular understanding of disease mechanisms, better models, patient stratification These challenges cannot be addressed by the healthcare industry alone: partnerships are a key component Page 4 2

3 Our partners value true collaborations with close interaction and exchange of expertise. What was valued and is important to our partners Impact on organizing the partnership Partners seek for Partner Collaborations on eye-level with close interaction, exchange of expertise and mutual benefit Clear strategy and long-term perspective generate added value for all involved parties complementary expertise Excellent collaboration partners Sharing of knowledge Feedback from our partners: Bayer Bayer has high scientific expertise and good partnership management Excellent internal Drug Discovery expertise Long-term, reliable partnership Good partner interaction High level of mutual trust which allows for in-depth sharing of knowledge. ¹ Page 5 ¹ Insights based on a survey conducted with 52 partners from Biotech (23), CROs (3), and Academia (26) in May/June An integrated partnering approach to generate added value for all parties is key to success. Innovative and tailored Partnering Models 1 Internal Organization and processes: We focus on excellence in alliance and partnership management Added Value 2 Tailored and innovative partnering models: We focus on-eye-level` partnerships Internal Organizational Structures and Processes People s skills, partnering culture and mindset 3 Appropriate Skill set and open culture: We foster an open culture and skills by trainings and open innovation concepts Partnering is part of our Global Drug Discovery organization as an integrated function: Global External Innovation & Alliances Page 6 3

4 Partnerships are an integrative part of Global Drug Discovery Global External Innovation & Alliances is part of BHC Global Drug Discovery Global External Innovation & Alliances focuses on: Development & management of strategic alliances & open innovation initiatives Research Policy and public funding Strategic Outsourcing VC Investments Local Hubs: Innovation Center China Science Hub US Science Hub Singapore San Francisco Boston Headquarter Berlin Beijing Singapore Global External Innovation & Alliances is responsible for research partnering activities of Bayer HealthCare Global Drug Discovery Page 7 ¹ Global Drug Discovery Bayer HealthCare s approach of flexible partnering models Within BHC Type Involvement Examples Joint labs Close interaction, shared labs DKFZ Strategic innovation partnership Consortia Multiple projects, close interaction Broad Institute, Evotec Innovative Med.Initiative Joint research Crowdsourcing Outsourcing Individual project Singapore Network G4T, G4L Wuxi Apptech Licensing Transition of assets LDC Dortmund Incubator Arm s length CoLaborator SF/Berlin Venture Investments High Tech Gründerfonds Strategic Alliances and Open Innovation approaches are key elements for Breakthrough Innovation Page 8 4

5 Novel partnership models: Strategic alliance Bayer Healthcare and the German Cancer Research Center Strategic Alliance and Joint Lab of Bayer, DKFZ and NCT Heidelberg German Cancer Research Center (DKFZ) is one of the largest biomedical oncology research centers in Europe First agreement signed in 2009, collaboration extended for another 5 years in 2014 Collaboration along the entire drug discovery and development value chain Novel risk and reward sharing approach to collaborate with joint financing (up to 30 mio EUR within the next 5 y) and project selection (currently 26 joint projects) Extension of partnership by joint laboratory for immunotherapies at the National Center for Tumor Diseases (NCT) in Heidelberg in 2013 Bench Bedside Page 9 BHC Open Innovation Family Grants4Targets Grants4Leads Grants4Apps CoLaborator BHC grants for targets/ biomarkers. Offers expertise, tools and technologies to help develop your ideas. BHC grants to assess small molecule leads which may lead to collaborations to explore such leads. BHC grants for innovative IT projects which may lead to new business models. Unique incubator for startup life-science companies aligning with Bayer s interests. San Francisco Berlin com com apps.com com Page 10 5

6 Novel type of partnering: Crowd Sourcing Challenge* to be solved defined by seeking institution (pharma company) Internet as communication platform Review Collaboration (industry and academia) to address challenges Solutions/ideas provided by scientific community * such as the search for novel targets, compounds or indications for known assets Source: Lessl et al., 2011, Nature Drug Discovery 10, Page 11 Crowd sourcing: Page 12 6

7 Novel Type of partnering our Grants4Targets Initiative Background Numerous targets exist, but are invisible for us The knowledge outside > inside Idea Join forces with academia and biotech start ups to translate innovative targets into drugs Provision of grants to evaluate and validate novel targets Grants 4 Targets Approach Easily accessible Internet site and submission tool Low bureaucratic burden for both partners Clear communication on needs what are we looking for? Fast processing of requests Target Discovery Lead Generation Lead Optimization Preclinical Clinical Submission Page 13 Grant types within G4T program Support Grants ( 5,000-10,000) to further advance research on targets that are at a very early stage of discovery; fixed grant approval letter; IP rights remain with the applicant Focus Grants ( 10, ,000) for more mature ideas, e.g. to address specific aspects of a target as a first step towards transferring it to the drug-discovery process; fixed grant approval letter; IP rights remain with the applicant 7

8 Visitors [-] Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug Sep Oct Nov Dec Jan Feb Mar Apr May Jun Jul Aug G4T is running for 5 years and has completed 10 rounds of applications 1027 applications received 133 grants approved (12% acceptance rate) Most of the ideas are novel to us 2% 24% 9% 7% 22% 38% Germany Europe w/o D USA Asia RoW 55% 11% 11% 7% 14% marketed ongoing BSP project under evaluation in-house terminated project no current project not applicable Lessl et al., Drug Discovery Today 2011, Vol 16, rounds of applications completed World-wide footprint Now attracting almost 3000 visitors / month 4000 Visitors per Month Month 15 Bayer is planning to open the CoLaborator in Berlin in May 2014 Key features 800 m 2 assigned lab and office space on Bayer HealthCare s campus in the heart of Berlin for up to 9 start-up companies A new home for startups in life sciences with ideas related to Bayer HealthCare s R&D strategy Proximity to Bayer HealthCare research and the vicinity to Berlin s science and startup community create an eco-system for innovative ideas. Page 16 8

9 VC investments to promote innovative start-ups in HealthCare Page 17 We apply the RESOLVE¹ model for professional Alliance Management incorporated in our research organization. Value of Relationship and Culture Focus on personal relationships: trust, respect Behave as real partners Create awareness and manage diversity Value communication Open communication and exchange of information, active conflict resolution Mutual feedback on performance Mutual Benefit and Added Value Enthusiasm / commitment Commitment at all levels Willingness to overcome resistance Share credit Strategic fit Identify match partners with complementary strengths / skills Complementary and transparent goals Learning capabilities Openness to learn from each other Value from cross-organizational learning Drivers / motivation of partners to be steered in common direction Professional operational management Well-defined processes Transparent governance Goal orientation, clear objectives Clear Agreements on IP publications and payments ¹ Lessl & Douglas: Wissenschaftsmanagement. (2) 2010, p Page 18 9

10 Collaborative Innovation is a key concept of our strategy Bayer HealthCare is committed to Innovation Science for a better Life Strategic Partnering on eye-level is an integral part of our Drug Discovery Strategy We strive for tailored partnering concepts generating added value for both parties An integrated partnering approach ensures pipeline impact and value generation for our patients Forward-Looking Statements This presentation may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer s public reports which are available on the Bayer website at The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments. 10

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015

AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 AT&T Global Network Client for Windows Product Support Matrix January 29, 2015 Product Support Matrix Following is the Product Support Matrix for the AT&T Global Network Client. See the AT&T Global Network

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS*

COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) CHARTERED BANK ADMINISTERED INTEREST RATES - PRIME BUSINESS* COMPARISON OF FIXED & VARIABLE RATES (25 YEARS) 2 Fixed Rates Variable Rates FIXED RATES OF THE PAST 25 YEARS AVERAGE RESIDENTIAL MORTGAGE LENDING RATE - 5 YEAR* (Per cent) Year Jan Feb Mar Apr May Jun

More information

Analysis One Code Desc. Transaction Amount. Fiscal Period

Analysis One Code Desc. Transaction Amount. Fiscal Period Analysis One Code Desc Transaction Amount Fiscal Period 57.63 Oct-12 12.13 Oct-12-38.90 Oct-12-773.00 Oct-12-800.00 Oct-12-187.00 Oct-12-82.00 Oct-12-82.00 Oct-12-110.00 Oct-12-1115.25 Oct-12-71.00 Oct-12-41.00

More information

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8

Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138. Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 1 of 138 Exhibit 8 Case 2:08-cv-02463-ABC-E Document 1-4 Filed 04/15/2008 Page 2 of 138 Domain Name: CELLULARVERISON.COM Updated Date: 12-dec-2007

More information

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se

Automating Cell Biology Annual general meeting, September 7, 2015. Phase Holographic Imaging www.phiab.se Automating Cell Biology Annual general meeting, September 7, 2015 www.phiab.se 1 PHASE HOLOGRAPHIC IMAGING (PHI) Began as a research project at Lund University, Sweden, in 2000 Founded in 2004 Sales in

More information

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017

Enhanced Vessel Traffic Management System Booking Slots Available and Vessels Booked per Day From 12-JAN-2016 To 30-JUN-2017 From -JAN- To -JUN- -JAN- VIRP Page Period Period Period -JAN- 8 -JAN- 8 9 -JAN- 8 8 -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- -JAN- 8-JAN- 9-JAN- -JAN- -JAN- -FEB- : days

More information

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors

Prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation (AF) with one or more risk factors News Release For use outside the US and UK only Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer s Xarelto Approved in the EU for the Prevention of Stroke in Patients

More information

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media

Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com. News Release. Not intended for U.S. and UK Media News Release Not intended for U.S. and UK Media Bayer Pharma AG 13342 Berlin Germany Tel. +49 30 468-1111 www.bayerpharma.com Bayer Forms Collaboration with Academic and Governmental Institutions for Rivaroxaban

More information

Investor News. Not intended for U.S. and UK media

Investor News. Not intended for U.S. and UK media Investor News Not intended for U.S. and UK media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer s Xarelto (Rivaroxaban) Approved for the Treatment of Pulmonary Embolism

More information

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention

Bayer Initiates Rivaroxaban Phase III Study to Support Dose Selection According to Individual Benefit-Risk Profile in Long- Term VTE Prevention Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Long-term prevention of venous blood clots (VTE): Bayer Initiates Rivaroxaban

More information

Analytic-Driven Quality Keys Success in Risk-Based Contracts. Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst

Analytic-Driven Quality Keys Success in Risk-Based Contracts. Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst Analytic-Driven Quality Keys Success in Risk-Based Contracts March 2 nd, 2016 Ross Gustafson, Vice President Allina Performance Resources, Health Catalyst Brian Rice, Vice President Network/ACO Integration,

More information

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer

Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment of Life-Threatening Blood Clots in Patients with Cancer Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Xarelto for the Prevention and Treatment

More information

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S.

Investor News. Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint. Not intended for U.S. Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Phase III J-ROCKET AF Study of Bayer s Xarelto (rivaroxaban) Meets Primary Endpoint

More information

Employee performance management in a global setting. Brenda Wilson

Employee performance management in a global setting. Brenda Wilson Employee performance management in a global setting Brenda Wilson Performance management overview What is performance management? Performance management is a CORE business process driven by business strategy,

More information

Abbott Diagnostics. Durable Growth Business

Abbott Diagnostics. Durable Growth Business Abbott Diagnostics Durable Growth Business Forward-Looking Statement Some statements in this presentation may be forward-looking statements for purposes of the Private Securities Litigation Reform Act

More information

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto

How To Get A Dose Of Bayer Healthcare'S Oral Anticoagulant, Xarelto News Release FOR UK HEALTHCARE MEDIA ONLY Bayer HealthCare Bayer plc Bayer House Strawberry Hill Newbury Berkshire, RG14 1JA www.bayer.co.uk Bayer s Xarelto (rivaroxaban) Recommended by CHMP for EU Approval

More information

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis

Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Outsourcing and Offshoring of R&D in the Pharmaceutical Industry: Evidence and Policy Implications from a Global Value Chain Analysis Paulina Ramirez: Birmingham Business School IRIMA Workshop on the Internationalisation

More information

Equipping your Forecasting Toolkit to Account for Ongoing Changes

Equipping your Forecasting Toolkit to Account for Ongoing Changes Equipping your Forecasting Toolkit to Account for Ongoing Changes Presented by: Roger Parlett Supply Chain Manager January 23, 2014 Overview Forecast Set-up Objectives of Creating a Forecast Identify Critical

More information

WE ENGINEER THE FUTURE INVESTOR PRESENTATION AUGUST, 2015

WE ENGINEER THE FUTURE INVESTOR PRESENTATION AUGUST, 2015 WE ENGINEER THE FUTURE INVESTOR PRESENTATION AUGUST, 2015 FIRST SENSOR COMPANY PROFILE First Sensor AG is one of the world's leading suppliers in the field of sensor systems. Our company develops and manufactures

More information

Consumer ID Theft Total Costs

Consumer ID Theft Total Costs Billions Consumer and Business Identity Theft Statistics Business identity (ID) theft is a growing crime and is a growing concern for state filing offices. Similar to consumer ID theft, after initially

More information

Ashley Institute of Training Schedule of VET Tuition Fees 2015

Ashley Institute of Training Schedule of VET Tuition Fees 2015 Ashley Institute of Training Schedule of VET Fees Year of Study Group ID:DECE15G1 Total Course Fees $ 12,000 29-Aug- 17-Oct- 50 14-Sep- 0.167 blended various $2,000 CHC02 Best practice 24-Oct- 12-Dec-

More information

FY 2015 Schedule at a Glance

FY 2015 Schedule at a Glance Coaching and Mentoring for Excellence Oct 21 23, 2014 $2,950 Residential Coaching and Mentoring for Excellence Apr 7 9, 2015 $2,400 Non-residential Coaching and Mentoring for Excellence May 27 29, 2015

More information

Transforming relationships Unleashing innovation

Transforming relationships Unleashing innovation Transforming relationships Unleashing innovation Translating Discoveries Into Products A model for innovation driven economic growth Barbara Handelin, PhD 1 The Innovation Gap Economic Opportunity Industries

More information

Quest for Growth Results for Q3, January-March 2003

Quest for Growth Results for Q3, January-March 2003 Quest for Growth Results for Q3, January-March 2003 1 Jan Keuppens joins Quest Management Investment Manager Quoted Portfolio of Quest for Growth Former technology analyst with AXA Investment Managers,

More information

Biotech Opportunities for Start-Up Firms in Japan and Asia

Biotech Opportunities for Start-Up Firms in Japan and Asia Biotech Opportunities for Start-Up Firms in Japan and Asia - Corporate VC s Perspective - Yoshitaka Yoneyama, Ph.D. President & CEO Astellas Venture Management LLC. April 25, 2006 About Astellas Pharma

More information

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism

Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of Unmet Medical Need in Arterial Thromboembolism Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Extends Clinical Investigation of Rivaroxaban into Important Areas of

More information

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative

2009 Foley & Lardner LLP Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative Attorney Advertising Prior results do not guarantee a similar outcome Models used are not clients but may be representative of clients 321 N. Clark Street, Suite 2800, Chicago, IL 60654 312.832.4500 Life

More information

Industry view: Managing complex research and innovation portfolios in today s innovation environment. Thomas Görgen

Industry view: Managing complex research and innovation portfolios in today s innovation environment. Thomas Görgen Industry view: Managing complex research and innovation portfolios in today s innovation environment Thomas Görgen 150 years Bayer Science For A Better Life Page 2 Taftie - Industry view Thomas Görgen

More information

About CREST R&D Grant

About CREST R&D Grant 1 About CREST R&D Grant Philosophy Higher value Electrical & Electronics (E&E) economic sector can be achieved when R&D thrives in the ecosystem This can be accelerated by promoting collaborative research

More information

Hot Line Session at European Society of Cardiology (ESC) Congress 2014:

Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Hot Line Session at European Society of Cardiology (ESC) Congress 2014: Once-Daily

More information

Project Management. Dissemination and Exploitation Services in Horizon 2020

Project Management. Dissemination and Exploitation Services in Horizon 2020 Project Management Dissemination and Exploitation Services in Horizon 2020 Ontwerp: Studio Edwin de Boer 2 Project Management Dissemination and Exploitation Services in Horizon 2020 ttopstart - Project

More information

Credit Suisse Healthcare Conference

Credit Suisse Healthcare Conference Credit Suisse Healthcare Conference November 14, 2013 Safe Harbor Statement 2 Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: To the extent any statements made in this

More information

Dipl. Kfm. Mario Hose, CEO

Dipl. Kfm. Mario Hose, CEO GERMAN DAY AT PDAC 2015. Dipl. Kfm. Mario Hose, CEO Project Financing Through German Partners March 3, 2015, 4:55 5:55pm Deal drivers Three parameters are the foundation for a successful deal! 1. Management

More information

CENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR

CENTERPOINT ENERGY TEXARKANA SERVICE AREA GAS SUPPLY RATE (GSR) JULY 2015. Small Commercial Service (SCS-1) GSR JULY 2015 Area (RS-1) GSR GSR (LCS-1) Texarkana Incorporated July-15 $0.50690/Ccf $0.45450/Ccf $0.00000/Ccf $2.85090/MMBtu $17.52070/MMBtu Texarkana Unincorporated July-15 $0.56370/Ccf $0.26110/Ccf $1.66900/Ccf

More information

Bayer Accelerates Clinical Development of Promising New Drug Candidates

Bayer Accelerates Clinical Development of Promising New Drug Candidates Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Bayer Accelerates Clinical Development of Promising New Drug Candidates Five

More information

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer

NORTH CAROLINA STATE UNIVERSITY NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer NORTH CAROLINA STATE UNIVERSITY Office of Technology Transfer putting ideas to work March 2007 Dr. Rob Whitehead Associate Director, Office of Technology Transfer March 2008 Research Extensive, Land-grant

More information

The Commercialization of Technology Concepts into Medical Products

The Commercialization of Technology Concepts into Medical Products The Commercialization of Technology Concepts into Medical Products Kevin J. Scanlon, Ph.D. New Zealand 2006 International BioScience Overview Pharmaceutical Industry Biotechnology Startups Investment Community

More information

Singapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study

Singapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study JOINT PRESS RELEASE EMBARGO TILL 7 August 2007, 1130 HOURS Singapore to conduct Phase 2 Clinical Trial of Abbott s Drug Candidate following successful First-in-human Phase 1 Study A Singapore team of physician

More information

Apples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI

Apples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI Apples Review of 2012/13 season Prognosfruit - Congress 2013 Helwig Schwartau, AMI Market balance for table apples in EU-27 1.000 tons 2009/10 2010/11 2011/12 2012/13f Market production 10.984 9.651 10.663

More information

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation

New Real-World Evidence Reaffirms Low Major Bleeding Rates for Bayer s Xarelto in Patients with Non-Valvular Atrial Fibrillation Investor News Not intended for U.S. and UK Media Bayer AG Investor Relations 51368 Leverkusen Germany www.investor.bayer.com Late-Breaking Science at ESC Congress 2015: New Real-World Evidence Reaffirms

More information

Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.

Clinical Trial Trends Outline Complexity for Supply Chain. Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken. Clinical Trial Trends Outline Complexity for Supply Chain Scott Ohanesian, VP Commercial Operations APAC Email: Scott.Ohanesian@marken.com 29 May 2013 Biotechnology Sales on the Rise Source: EvaluatePharma

More information

Big Data An Opportunity or a Distraction? Signal or Noise?

Big Data An Opportunity or a Distraction? Signal or Noise? Big Data An Opportunity or a Distraction? Signal or Noise? Maya R. Said, Sc.D. SVP & Global Head, Oncology Policy & Market Access, Novartis 3rd International Systems Biomedicine Symposium Luxembourg, 28

More information

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com

Life Science Sector Opportunities Northern Ireland. Clinical Trials. investni.com Life Science Sector Opportunities Northern Ireland investni.com Introduction Clinical trials commonly refer to testing the effectiveness of experimental drugs and are typically categorised into four phases;

More information

MOBILE AD TRENDS 2015

MOBILE AD TRENDS 2015 MOBILE AD S 2015 INNERACTIVE KEY S Inneractive s mobile programmatic platform processes billions of ad requests daily from around the world. We are strong believers in leveraging our data in order to provide

More information

Eudendron: an Innovative Biotech Start-up

Eudendron: an Innovative Biotech Start-up Eudendron: an Innovative Biotech Start-up Mauro Angiolini & Fabio Zuccotto I Venti dell Innovazione, Ville Ponti - Varese, 20 Marzo 2013 Bioindustry Park S. Fumero (Ivrea) - Italy Eudendron: a Quick Description

More information

Clinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com

Clinical Trials. In Singapore. Clinical Trials in Asia Pacifi c. Introduction. Healthcare Clusters. www.asiabiotech.com Clinical Trials In Singapore Dr Say-Beng Tan, Dr Eugene Fidelis Soh, and Dr Han-Chong Toh Introduction Clinical trials are the gold standard for the evaluation of new treatment strategies. New treatments

More information

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121

Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 NHLBI SAN DIEGO INNOVATION CONFERENCE JUNE 11, 2013 Janssen Research & Development 3210 Merryfield Row San Diego, CA 92121 Agenda Speaker Bios 10:30-11:00 a.m. Registration 11:00-11:15 a.m. Welcome Remarks

More information

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum

Open Innovation: An Imperative for the Pharmaceutical Industry. Berkeley Innovation Forum Open Innovation: An Imperative for the Pharmaceutical Industry Berkeley Innovation Forum October 28-29, 2010 Minneapolis, MN Ted Torphy, Ph.D. Vice President & Head External Innovation Research Capabilities

More information

RBC Insurance Fetes Online Auto/Home Insurance Growth

RBC Insurance Fetes Online Auto/Home Insurance Growth Case Studies, K. Harris Research Note 29 October 2002 RBC Insurance Fetes Online Auto/Home Insurance Growth RBC Insurance's e-business successes are generating greater than $3 million in premiums per month.

More information

Bayer Technology Services

Bayer Technology Services Bayer Technology Services Company Profile 2013 (updated 1-Mar-2014) Page 1 Facts & Figures Portfolio Page 2 Bayer Technology Services a Bayer Subsidiary Holding company Group Management Board Bayer AG

More information

Oncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING

Oncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING Oncology Central MEDIA PACK 2016 SPONSORSHIP ADVERTISING NETWORKING Client opportunities CONTENTS About us...02 Readership...04 Driving qualified leads...05 Our Journals...08 Editorial Calendar...10 Rate

More information

EDI Services helps healthcare network streamline workflow, increase productivity, and improve revenue cycle management.

EDI Services helps healthcare network streamline workflow, increase productivity, and improve revenue cycle management. GE Healthcare Results summary 2008 2010 Reduced eligibility rejection rate from 2% to 0.8% Reduced overall rejection rate from 6.4% to 4% Reduced cost to collect from 8.3% to 6.3% Increased the number

More information

www.pwc.com/us/assetmanagement US Asset Management Strategic Imperatives for Asset Managers May 2013

www.pwc.com/us/assetmanagement US Asset Management Strategic Imperatives for Asset Managers May 2013 www.pwc.com/us/assetmanagement US Asset Management Strategic Imperatives for Asset Managers May 2013 Table of contents Executive summary 1 Macro trends 2 Rise and interconnectivity of the emerging markets

More information

MOLOGEN AG German Equity Forum 2015

MOLOGEN AG German Equity Forum 2015 German Equity Forum 2015 Dr. Mariola Söhngen Chief Executive Officer Frankfurt am Main 24 November 2015 We are Pioneers in the Field of Immunotherapies Biotechnology company with focus on immunotherapies

More information

A leader in the development and application of information technology to prevent and treat disease.

A leader in the development and application of information technology to prevent and treat disease. A leader in the development and application of information technology to prevent and treat disease. About MOLECULAR HEALTH Molecular Health was founded in 2004 with the vision of changing healthcare. Today

More information

Children's Hospital Boston - Strategic SWOT Analysis Review

Children's Hospital Boston - Strategic SWOT Analysis Review Brochure More information from http://www.researchandmarkets.com/reports/1837823/ Description: Summary Children's Hospital Boston (Children s) is the pediatric medical center that provides a full range

More information

Join our scientific talent community

Join our scientific talent community Join our scientific talent community There has never been a better time to be a part of Janssen Research & Development. We are at the forefront of healthcare leading, evolving and transforming it into

More information

Tim Howkins, CEO. Steve Clutton, Finance Director

Tim Howkins, CEO. Steve Clutton, Finance Director Tim Howkins, CEO Steve Clutton, Finance Director Highlights Revenue Revenue up 36% Earnings per share up 33% All parts of business contributed to growth Benefits of increased IT spend Proposed final dividend

More information

Investor science conference call: American College of Cardiology 2015

Investor science conference call: American College of Cardiology 2015 Investor science conference call: American College of Cardiology 2015 San Diego, California, USA 16 March 2015 Cautionary statement regarding forward-looking statements In order, among other things, to

More information

Groundbreaking Collaborative Clinical Trial Launched

Groundbreaking Collaborative Clinical Trial Launched Groundbreaking Collaborative Clinical Trial Launched For immediate release Media Contacts: June 16, 2014 Richard Folkers Alison Hendrie 9:00 a.m., EDT Foundation for the NIH Rubenstein Communications (301)

More information

RIIO-T1 business plan submission London Tuesday 6 September 2011

RIIO-T1 business plan submission London Tuesday 6 September 2011 RIIO-T1 business plan submission London Tuesday 6 September 2011 Cautionary statement This presentation contains certain statements that are neither reported financial results nor other historical information.

More information

NATIONAL CREDIT UNION SHARE INSURANCE FUND

NATIONAL CREDIT UNION SHARE INSURANCE FUND NATIONAL CREDIT UNION SHARE INSURANCE FUND PRELIMINARY & UNAUDITED FINANCIAL HIGHLIGHTS RENDELL L. JONES CHIEF FINANCIAL OFFICER MANAGEMENT OVERVIEW Balance Sheet Other - Insurance and Guarantee Program

More information

Corporate Prospectus January 2015

Corporate Prospectus January 2015 Corporate Prospectus January 2015 1000 Morris Ave, STEM Bldg., Union, NJ 07083 Tel: (908) 737-1922 Fax: (908) 737-1924 www.ilsebio.com The Institute for Life Science Entrepreneurship (ILSE) is a regional

More information

Integrated Business planning in

Integrated Business planning in Integrated Business planning in Philips Consumer Lifestyle Eelco van den Akker Philips Consumer Lifestyle 10 februari 2010 IBM Forum, Amsterdam Agenda Philips Consumer Lifestyle Business Planning Demand

More information

S&OP Case Study Creating Value at O Neal Manufacturing Services. Anthony Zampello, CPIM, CIRM, CSCP Adjunct Faculty Bentley University

S&OP Case Study Creating Value at O Neal Manufacturing Services. Anthony Zampello, CPIM, CIRM, CSCP Adjunct Faculty Bentley University S&OP Case Study Creating Value at O Neal Manufacturing Services Anthony Zampello, CPIM, CIRM, CSCP Adjunct Faculty Bentley University Prepared by: Jamie Cochran, Strategic Business Applications Manager,

More information

How To Understand The Third Platform Ct Market Transformation In Latin America

How To Understand The Third Platform Ct Market Transformation In Latin America Latin America 4 Pillars of the Third Platform Continuous Information Series Value Proposition June 2014 International Data Corporation (IDC) is the premier global provider of market intelligence, advisory

More information

The Cell Therapy Catapult

The Cell Therapy Catapult The Cell Therapy Catapult Keith Thompson CEO January 29 2013 info@ct.catapult.org.uk Catapult is a Technology Strategy Board programme The Launch of Catapults Hauser 2 Hauser Report Creating new manufacturing

More information

BASF Venture Capital GmbH

BASF Venture Capital GmbH BASF Venture Capital GmbH Investment Strategy for Nanotechnology and Advanced Materials EuroNanoForum Riga 2015 Disclaimer This presentation contains forward-looking statements under the US Private Securities

More information

Medium Term Management Plan Next 100 Transform to Grow

Medium Term Management Plan Next 100 Transform to Grow Medium Term Management Plan Conference in Tokyo (June 17, 2014) NIKON CORPORATION Forward-looking statements for earnings and other performance data contained herein are based on information currently

More information

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014

Location for Trials- Global Considerations A Pharma Perspective. Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Location for Trials- Global Considerations A Pharma Perspective Carlo Maccarrone Assoc. Director, Clinical Research GSK Australia 7 May 2014 Why Choose Australia for Clinical Trials? What is he saying

More information

Craig Hallum Conference Investor Presentation

Craig Hallum Conference Investor Presentation Craig Hallum Conference Investor Presentation Improving cancer outcomes with groundbreaking precision in molecular testing Paul Kinnon President and CEO Sept 2015 1 Forward-Looking Statements Certain statements

More information

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals

The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals The Geography of Markets for Technology: Evidence from Bio- Pharmaceuticals Michelle Gittelman Department of Business and Management Rutgers Business School Newark-New Brunswick, New Jersey The pharmaceutical

More information

Engaging Clinical Trial Sites:

Engaging Clinical Trial Sites: WHITE PAPER Engaging Clinical Trial Sites: The Role of the Clinical Trial Liaison Author: MARTIN LEE, MD Vice President, Global Scientific Affairs PRA Health Sciences Key Customers in Clinical Research

More information

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010

U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade. N8B7-52 December 2010 U.S. Contract Research Outsourcing Market: Trends, Challenges and Competition in the New Decade December 2010 Table of Contents Notes on Methodology 8 Market Introduction and Segmentation Introduction

More information

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014

Marieme Ba for CAAST-NET + 1 st stakeholder meeting Entebbe November 2014 Coming together is a beginning, keeping together is progress, working together is success. - Henry Ford - Considering the clinical research industry as an area for enhanced public-private sector collaboration

More information

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover

BioMed Partners. The rocky way from science to market. Dr. Karsten Fischer BioMedPartners AG. VPM Days Hannover The rocky way from science to market Dr. Karsten Fischer BioMedPartners AG VPM Days Hannover November 2013 Content I. Stage 1 II. Setbacks 6 III. Hope 12 IV. Solutions 17 V. Expertise 20 Page 1 The Challenge

More information

www.pwc.com/bigdecisions Are you prepared to make the decisions that matter most? Decision making in retail

www.pwc.com/bigdecisions Are you prepared to make the decisions that matter most? Decision making in retail www.pwc.com/bigdecisions Are you prepared to make the decisions that matter most? Decision making in retail Results from PwC s Global Data & Analytics Survey 2014 retail Showrooming and mobile search.

More information

Spring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai

Spring 2013. From Our CEO. Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai From Our CEO Special Event WuXi Forum - Gateway to China Chinese Premier Li Keqiang Visits WuXi Headquarter in Shanghai Featured Story WuXi and PRA Form Joint Venture to Offer Clinical Research Services

More information

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset

Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Taking Strategic Partnerships to the Next Level: An Alternative Approach to Licensing Your Development Asset Introduction In this era of strategic development deals, inventiv Health has significantly broadened

More information

Strategic Consulting Services

Strategic Consulting Services Services 1 Leadership Team Mark Levonyak President mlevonyak@davaonc.com Mobile: 214.460.5051 Martin W. Lee, MD EVP, Clinical Trial Services mlee@davaonc.com Mobile: 952.373.1405 John Eckardt, MD Chief

More information

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure

Introduction. The Healthcare Sector in Asia - Current Situation. Projected Healthcare Expenditure Policy Issues in the Economics and Financing of Medical Technology in the Asia-Pacific Region Dr KAI HONG PHUA Joint Professor Yong Loo Lin School of Medicine and Lee Kuan Yew School of Public Policy National

More information

CAFIS REPORT 2015.10

CAFIS REPORT 2015.10 CAFIS REPORT 2015.10 INDEX Message CAFIS Inbound 03-06 07-08 CAFIS Arch 09-10 CAFIS Brain 11-12 CAFIS Global 13-14 What We Do 15-16 About CAFIS 17-18 Services for Member Stores 19-34 Services for Card

More information

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference

Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Exelixis Showcases R&D Pipeline at JPMorgan Healthcare Conference Two New Clinical Programs and Significant Expansion of Cancer Pipeline Planned for 2004 SOUTH SAN FRANCISCO, Calif., Jan. 13 /PRNewswire-FirstCall/

More information

PROJECTS SCHEDULING AND COST CONTROLS

PROJECTS SCHEDULING AND COST CONTROLS Professional Development Day September 27th, 2014 PROJECTS SCHEDULING AND COST CONTROLS Why do we need to Control Time and Cost? Plans are nothing; Planning is everything. Dwight D. Eisenhower Back to

More information

IntercontinentalExchange. Credit Suisse Financial Services Forum February 7, 2008

IntercontinentalExchange. Credit Suisse Financial Services Forum February 7, 2008 IntercontinentalExchange Credit Suisse Financial Services Forum February 7, 2008 Forward-Looking Statements Forward-Looking Statements This presentation may contain forward-looking statements made pursuant

More information

A vaccine for rheumatoid arthritis

A vaccine for rheumatoid arthritis A vaccine for rheumatoid arthritis Professor Ranjeny Thomas Founder and Director of Dendright Pty Limited Head, Autoimmunity Division, Diamantina Institute, The University of Queensland About Dendright

More information

EMR and ehr Together for patients and providers. ehealth Conference October 3-4, 2014

EMR and ehr Together for patients and providers. ehealth Conference October 3-4, 2014 EMR and ehr Together for patients and providers ehealth Conference October 3-4, 2014 DISCLOSURES: Commercial Interests NONE Susan Antosh is CEO of ehealth Saskatchewan Vision: Empowering Patients, Enabling

More information

Detailed guidance for employers

Detailed guidance for employers April 2015 3 Detailed guidance for employers Appendix A: Pay reference periods This document accompanies: Detailed guidance no. 3 Assessing the workforce Pay reference period calendars where the definition

More information

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015

APAC CRO Market A deep dive into the trends transforming APAC CRO industry. P86A-52 June 2015 APAC CRO Market A deep dive into the trends transforming APAC CRO industry June 2015 Table of Contents Section Slide Numbers Executive Summary 10 Key Findings 11 Total CRO Market Size By Stages of Clinical

More information

Financial Results. for FY 2010 ended March 2011. ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.

Financial Results. for FY 2010 ended March 2011. ~For healthy and affluent lives of people around the world~ http://www.transgenic.co. Financial Results for FY 2010 ended March 2011 ~For healthy and affluent lives of people around the world~ http://www.transgenic.co.jp May 24, 2011 TRANS GENIC INC. Note: This material includes forward-looking

More information

Meeting Priorities of Biotech & Small Pharma Companies

Meeting Priorities of Biotech & Small Pharma Companies Meeting Priorities of Biotech & Small Pharma Companies Dr. Andreas Orfanos, MBBCH,FFPM,MBA Thrasos Therapeutics Inc. Vice President Clinical Research & Development 28 Oct 2015 Montreal Technoparc Private,

More information

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder

The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases. Scott Johnson CEO, President and Founder The Myelin Repair Foundation: Accelerating New Treatments for Multiple Sclerosis and All Diseases Scott Johnson CEO, President and Founder Introduction Broken system of medical research No fault, system

More information

Even we will get to use your product someday. Enough reason for us to deliver.

Even we will get to use your product someday. Enough reason for us to deliver. Even we will get to use your product someday. Enough reason for us to deliver. ClinInvent: Putting our heart and soul behind the research. At ClinInvent, when we talk about clinical research it s not just

More information

Product Development Partnerships (PDPs): Overview

Product Development Partnerships (PDPs): Overview Product Development Partnerships (PDPs): Overview Product Development Boot Camp 6 November 2015 Dr. Ryan Wiley President Shift Health is a healthcare strategy consultancy devoted exclusively to healthcare

More information

NHS BLOOD AND TRANSPLANT MARCH 2009 RESPONDING EFFECTIVELY TO BLOOD DONOR FEEDBACK

NHS BLOOD AND TRANSPLANT MARCH 2009 RESPONDING EFFECTIVELY TO BLOOD DONOR FEEDBACK 09/26 NHS BLOOD AND TRANSPLANT MARCH 2009 RESPONDING EFFECTIVELY TO BLOOD DONOR FEEDBACK EXECUTIVE SUMMARY From April 2009 an NHS wide common approach to complaint handling comes in to effect. This provides

More information

Case Study: Sales to Trial to Marketing Life Cycle

Case Study: Sales to Trial to Marketing Life Cycle Case Study: Sales to Trial to Marketing Life Cycle Joanne White VP of Clinical Development Chitra Sundaram Assoc. Director- Enterprise Data Warehouse PAREXEL International, LLC Over $1 Billion in Annual

More information

Medical Billing and the Advantages of a Novelized Pharmaceutical Program

Medical Billing and the Advantages of a Novelized Pharmaceutical Program FOR IMMEDIATE RELEASE Compugen Ltd. Reports Fourth Quarter and Calendar 2015 Results Holon, ISRAEL February 9, 2016 Compugen Ltd. (NASDAQ: CGEN), a leading predictive drug discovery company, today reported

More information

WEATHERHEAD EXECUTIVE EDUCATION COURSE CATALOG

WEATHERHEAD EXECUTIVE EDUCATION COURSE CATALOG 2016 WEATHERHEAD EXECUTIVE EDUCATION COURSE CATALOG APPRECIATIVE INQUIRY COMMUNICATION AND PROFESSIONAL SKILLS EMOTIONAL INTELLIGENCE FINANCIAL DECISION MAKING DESIGNING INNOVATION AND STRATEGY MANAGING

More information

P/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015

P/T 2B: 2 nd Half of Term (8 weeks) Start: 24-AUG-2015 End: 18-OCT-2015 Start: 19-OCT-2015 End: 13-DEC-2015 2015-2016 SPECIAL TERM ACADEMIC CALENDAR For Scranton Education Online (SEOL), Masters of Business Administration Online, Masters of Accountancy Online, Health Administration Online, Health Informatics

More information